Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Epoetin alfa (Eprex) for anaemia in adults with low or intermediate-1 risk myelodysplastic syndromes. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Myelodysplastic syndromes are a group of rare diseases which affect the bone marrow – the part of the body where blood cells are made. In myelodysplastic syndromes, the bone marrow does not make enough healthy blood cells. This causes symptoms such as feeling weak, tired and breathless due to lack of red blood cells (anaemia).
Epoetin alfa is a drug not currently licensed but already used for the treatment of anaemia in adults with myelodysplastic syndromes that is injected under the skin. If epoetin alfa is licensed for use in the UK, it would be the first drug specifically for these patients, and could improve their quality of life. Indexing Status Subject indexing assigned by CRD MeSH Adult; Anemia; Epoetin Alfa; Erythropoietin; Humans; Myelodysplastic Syndromes; Risk Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000814 Date abstract record published 22/06/2016 |